Bachem Holding AG (0QND)
London Exchange · UK · prices in GBP · close of 20 Oct 2026
Key indicators
| Last close | GBP 85.45 |
|---|---|
| 52-week range | 48.70 – 85.75 |
| Return, 1 month / 3 months | +5.8% / +13.0% |
| Return, 1 year / 3 years | +55.7% / +27.3% |
| Trend | Uptrend |
| RSI (14) | 68 |
| Volatility (1 year) | 41.9% |
| Worst drawdown (1 year) | -27.0% |
| Average daily value traded | 1.47M GBP |
| Dividend yield | 0.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Bachem Holding is a Swiss company based in Bubendorf that makes peptides and other complex organic molecules for the pharmaceutical and biotechnology industries. It produces active pharmaceutical ingredients, research-grade peptides and related compounds, and it works as a contract manufacturer for drug developers as well as supplying generic peptide medicines. Its customers are mainly pharmaceutical and biotechnology companies that use these ingredients in medicines and in laboratory research.
The shares are listed on the London Exchange in UK under the code 0QND, and the price on this page is in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Bachem Holding AG (0QND) trades on the London Exchange in UK. It last closed at GBP 85.45 on 20 October 2026.
Its price-based Market X-Ray is 65 out of 100 (a fair price profile), ranking 874 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 55.7% and over the last three months it rose 13.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 89 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 19.6% | ||
| From 52-week high | 0.0% | ||
| Momentum | 84 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 13.0% | ||
| 6-month return | 26.3% | ||
| 12-month return, skipping the last month | 47.2% | ||
| Stability (higher is calmer) | 46 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 41.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -27.0% | ||
| Liquidity | 57 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.47M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | 20 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.0% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +6.1% |
|---|---|
| 1 month | +5.8% |
| 3 months | +13.0% |
| 6 months | +26.3% |
| 1 year | +55.7% |
| 3 years | +27.3% |
| 5 years | – |
Signals
| 50-day / 200-day average | 78.88 / 71.47 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.34 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 1 May 2026 | GBX 0.0045 |
| 2 May 2025 | GBX 0.0042 |
| 26 Apr 2024 | GBX 0.0040 |
| 21 Apr 2023 | GBX 0.0037 |
| 29 Apr 2022 | GBX 0.0175 |
| 30 Apr 2021 | GBX 0.0163 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.